Informatics Publishing Limited

Anupam Mitra ¹, Puneet Khanna ²

Affiliations
1 ACMA, SIBM, Bengaluru, IN
2 SIBM, Bengaluru, IN

Abstract

Introductory investments courses revolve around Harry Markowitz's modern portfolio theory and William Sharpe's Index for the performance measurement of those portfolios. This paper presents a simplified perspective of Markowitz's contributions to Modern Portfolio Theory. It is to see the effect of duration of historical data on the risk and return of the portfolio and to see the applicability of risk-reward logic. The empirical results also show that short selling may increase the risk of the portfolio when the investor is instability preferred.

Keywords

Markowitz Portfolio Theory, Sharpe Ratio, BSE, Stocks, India.

Full Text

   

Sandeep Nayar ¹, Puneet Khanna ², Pankaj Anand ³, N. K. Soni ⁴, Niraj Tyagi ⁵, Yashwant Dubey ⁶, Siddharth Patanwar ⁷, Aaditi Phadke ⁸, Parthasarathy Muralidharan ⁸, Amit Qamra ⁸

Affiliations
1 Senior Director and Head, BLK Centre for Chest & Respiratory diseases, BLK Super Speciality Hospital, New Delhi, IN
2 Senior Consultant and Head, Department of Interventional Pulmonology, Respiratory & Sleep Medicine, Manipal Hospitals, New Delhi, IN
3 Senior Consultant, Critical Care & Internal Medicine, Fortis Escorts Hospital, Jaipur, IN
4 Senior Consultant & Head- Internal Medicine & Diabetology. Yatharth Super Speciality Hospital, Greater Noida, IN
5 Consultant, Institute of Critical Care Medicine, Sir Ganga Ram Hospital, New Delhi, IN
6 Senior Consulting Physician, Arpan Sugar Clinic, Bilaspur, IN
7 Department of Pulmonary Medicine, AIIMS, Raipur, IN
8 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, IN

Abstract

The COVID‑19 pandemic has gripped the world in fear with more than 109 million cases and more than 2.4 million deaths as of 16th February 2021. After US, India has the second highest number of cases in the world. A pandemic of this scale has clearly become an unmet medical need warranting research on effective pharmaco-therapeutic agents. Given the time constraints, existing drugs have been repurposed to fill in the gap. Ivermectin is an FDA-approved broad spectrum antiparasitic agent. It is enlisted in the core list of WHO Model List of Essential Medicine 2019. Ivermectin is economical, easily available and safe without any major side effects. Recent research has shown that Ivermectin possesses strong anti-viral properties. It can also be safely combined with other repurposed drugs for Covid-19. Here, we review mechanism of action and current scientific evidence of Ivermectin in treatment and prophylaxis of Covid-19. A number of ongoing clinical trials are evaluating the drug further in the treatment and prophylaxis of Covid-19. Based on the current clinical evidence in treatment and prophylaxis, Indian Experts’ consensus and recommendations by multiple Indian state governments, Ivermectin may effectively and safely add to the current armamentarium of Indian clinicians involved in the care and management of Covid-19 patients.

Keywords

Ivermectin, Covid-19. SARS-CoV-2.

Full Text